OncoMatch/Clinical Trials/NCT06566547
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT06566547 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies GR1803 for multiple myeloma.
Treatment: GR1803 — All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: bcma-targeted therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify